24a) Other #TTR #stabilizers in development: 🫀 #Acoramidis (#AG10) in an ongoing phase 3 trial (#ATTRibute-CM trial, NCT03860935) looks to be well tolerated in patients with #ATTR_CM + symptomatic #HF. See 🔓 https://t.co/mGfMC7E703.
10) Other approaches to treating #ATTR_PN may emerge over the next few years, including gene editing with #CRISPR, new #TTR #stabilizers including #acoramidis & #tolcapone. For more info see: 👉🔓 https://t.co/fRx8p5pwDt 👉🔓 https://t.co/mGfMC7E703 👉🔓 htt
RT @HFpEF: Here is an example of how a TTR stabilizer can dramatically increase TTR (prealbumin) levels. This is from the Eidos AG10 phase…
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. https://t.co/w4E9FpHPoN
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
RT @MasriAhmadMD: Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer th…
Thread/ Dan Judge presented these data @AHAScience #AHA19 from the open label extension of #AG10 - a novel stabilizer that is currently undergoing phase III trial. Earlier in 2019, the phase II results were published in @JACCJournals https://t.co/jjJvnG
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
RT @jpcostabel: Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y e…
Nuevo agente estabilizador de TTR para amiloidosis cardíaca by my friend @maz_hanna and cols. ➡️ estudio de seguridad y eficacia: fase 2 ➡️ 400 y 800 mg cada 12 hs vo. ➡️ 100 % de estabilización de TTR plasm ➡️ exc tolerabilidad. 🔜 Fase 3 ongoing. htt
RT @CSHeartResearch: Exciting stuff @HeitnerStephen , Dan Judge and Team. Great hope for amyloid cardiomyopathy patients. Well done 👍🏻 http…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @CSHeartResearch: Exciting stuff @HeitnerStephen , Dan Judge and Team. Great hope for amyloid cardiomyopathy patients. Well done 👍🏻 http…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
RT @JACCJournals: New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopath…
★★★ Still not inovative. Not surprising.
New #JACC study examines the effectiveness of AG10, a selective, oral TTR stabilizer for patients with ATTR cardiomyopathy. Could a new therapy be on the horizon? https://t.co/B7qptpEYAB @HeitnerStephen https://t.co/K5YKjSJrtA
Check out this paper: https://t.co/mf8qJs3LgJ (via @papersapp) Transthyretin Stabilization by AG10 in Symptomatic Transthyretin #Amyloid Cardiomyopathy #ATTR
Eidos is proud to share publication in JACC of our Phase 2 study of AG10 in patients with ATTR-CM. Congratulations to our two co-first authors, Dan Judge (MUSC, Charleston SC) and Steve Heitner (OHSU, Portland OR), on this very nice paper: https://t.co/De3
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy https://t.co/CeC4NAWP87
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. https://t.co/OAcbfTCJRR
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. https://t.co/w4E9FpHPoN
AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant TTR amyloid cardiomyopath . Pure magic happening in the amyloid world right now. Check out: Judge DP et. al doi: https://t.co/9ymKVnqSNw. https://t.co/LVr5T6ID1W